Compare · LAB vs RVTY
LAB vs RVTY
Side-by-side comparison of Standard BioTools Inc. (LAB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LAB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 66.4x LAB ($259.8M).
- Both names hit the wire about 7 times in the past 4 weeks.
- RVTY has more recent analyst coverage (23 ratings vs 5 for LAB).
- Company
- Standard BioTools Inc.
- Revvity Inc.
- Price
- $0.64-2.29%
- $152.62-1.34%
- Market cap
- $259.8M
- $17.26B
- 1M return
- -12.99%
- -
- 1Y return
- -49.79%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- News (4w)
- 7
- 7
- Recent ratings
- 5
- 23
Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Latest LAB
- Amendment: SEC Form S-4/A filed by Standard BioTools Inc.
- SEC Form 425 filed by Standard BioTools Inc.
- SEC Form 8-K filed by Standard BioTools Inc.
- Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
- SEC Form 425 filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Standard BioTools Provides Update on Sale of Mass Cytometry Business
- Amendment: SEC Form S-4/A filed by Standard BioTools Inc.
- SVP & Chief Business Officer Mackay Sean covered exercise/tax liability with 25,729 shares, decreasing direct ownership by 2% to 1,480,823 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Kim Hanjoon Alex covered exercise/tax liability with 28,195 shares, decreasing direct ownership by 1% to 2,534,859 units (SEC Form 4) (for withholding tax)
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery